Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 9, 2005, Pages 831-838

  Erichsen, K ^a,b   Ulvik, R J ^a,b   Grimstad, T ^c   Berstad, A ^a   Berge, R K ^a   Hausken, T ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANTIOXIDANT; FERROUS SULFATE; IRON POLYMALTOSE; MALONALDEHYDE; MALTOFER FILMTABLETS; NYCOPLUS FERRO RETARD;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; LIPID PEROXIDATION; MALE; NAUSEA; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TISSUE INJURY; URINE;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; DINOPROST; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HEMATINICS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; TABLETS; VASOCONSTRICTOR AGENTS;

EID: 27644588712     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02652.x     Document Type: Article

References (30)

1. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-7.
2. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol Ther 2002; 16: 1997-2015.
3. Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr 1999; 69: 250-5.
4. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001; 15: 1989-99.
5. Uritski R, Barshack I, Bilkis I, Ghebremeskel K, Reifen R. Dietary iron affects inflammatory status in a rat model of colitis. J Nutr 2004; 134: 2251-5.
6. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42: 1439-52.
7. Jacobs P, Wood L, Bird AR. Erythrocytes: better tolerance of iron-polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematol 2000; 5: 77-83.
8. Svardal AM, Mansoor MA, Ueland PM. Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography. Anal Biochem 1990; 184: 338-46.
9. Vaagenes H, Muna ZA, Madsen L, Berge RK. Low doses of eicosapentaenoic acid, docosahexaenoic acid, and hypolipidemic eicosapentaenoic acid derivatives have no effect on lipid peroxidation in plasma. Lipids 1998; 33: 1131-7.
10. Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE. Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 1995; 667: 199-208.
11. Lee CY, Jenner AM, Halliwell B. Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry. Biochem Biophys Res Commun 2004; 320: 696-702.
12. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36: 291-6.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
14. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
15. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
16. Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998; 28: 659-71.
17. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol 2003; 38: 543-8.
18. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 2002; 132: 3146-50.
19. Erichsen K, Milde AM, Arslan G, et al. Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis 2005; 11: 744-8.
20. Reifen R, Matas Z, Zeidel L, Berkovitch Z, Bujanover Y. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci 2000; 45: 394-7.
21. Tuomainen TP, Nyyssonen K, Porkkala-Sarataho E, et al. Oral supplementation with ferrous sulfate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutrition Research 1999; 19: 1121-32.
22. Kavakli K, Yilmaz D, Cetinkaya B, Balkan C, Sozmen EY, Sagin FG. Safety profiles of Fe2+ and Fe3 + oral preparations in the treatment of iron deficiency anemia in children. Pediatr Hematol Oncol 2004; 21: 403-10.
23. Singh RK, Barrand MA. Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate. J Pharm Pharmacol 1990; 42: 276-9.
24. Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998; 12: 845-8.
25. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18: 319-32.
26. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-65.
27. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 823-5.
28. Geisser P, Muller A. Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes. Arzneimittelforschung 1987; 37: 100-4.
29. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984; 15: 367-77.
30. Johnson G, Jacobs P. Bioavailability and the mechanisms of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals. Exp Hematol 1990; 18: 1064-9.